RayKnowChina Research Map
Shortlist

ShanghaiNaval Medical University

Changhai Hospital

海军军医大学第一附属医院(长海医院)

Listed for 18 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Changhai Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌2 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌22 papers led1 open trial led
  3. Hepatocellular carcinoma肝细胞癌19 papers led
  4. Stomach cancer胃癌31 papers led5 open trials led
  5. Retinoblastoma视网膜母细胞瘤2 papers led
  6. Osteosarcoma骨肉瘤1 paper led
  7. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  8. Neuroblastoma神经母细胞瘤0 papers led
  9. IgG4-related diseaseIgG4相关性疾病0 papers led1 open trial led
  10. Takayasu arteritis大动脉炎1 paper led
  11. Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
  12. Behçet disease白塞病0 papers led
  13. IgA nephropathyIgA 肾病1 paper led
  14. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  15. Congenital diaphragmatic hernia先天性膈疝0 papers led
  16. Hirschsprung disease先天性巨结肠0 papers led
  17. Inherited epidermolysis bullosa遗传性大疱性表皮松解症1 paper led
  18. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Hepatoblastoma, Chordoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 2 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.08%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

10 hospitals in Shanghai for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Adjuvant vs Surgery Only in Early-stage Recurrent NPC
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06228079

    Age 18 years to 75 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen

  2. Recruiting
    Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
    Phase
    Phase 3
    Started
    2024-07
    Registry
    NCT06235203

    Age 18 years to 75 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueInduction / concurrent chemotherapyImmunotherapy
Departments in papersENT / head & neck surgery

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 22 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
22
2021–2025
Trials led
7
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 1120222023: 3320232024: 6620242025: 772025

18 hospitals in Shanghai for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Enrolling by invitation
    Diagnostic Accuracy of Endocytoscopy for Superficial Esophageal Neoplasia
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT06984055

    Age 18 years to 85 years (registered criteria)

    Led by Changhai HospitalShanghai

  2. Recruiting
    Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2019-09
    Registry
    NCT04135664

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest Hospital; 5 listed hospitals as study sitesNanchang, Shanghai, Tianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopyImaging & AIMolecular markers & genomics
Departments in papersGastroenterology / hepatologyMedical oncology
Papers it led22
  1. Development and validation of a multimodal deep learning model for early esophageal squamous neoplasia detection and invasion depth prediction.2026Endoscopy
  2. Accurate Nonendoscopic Detection of Early Esophageal Squamous Malignant Lesions Using Sponge-Based Methylated DNA Biomarkers.2026The American journal of gastroenterology
  3. Prognostic and clinicopathological significance of tertiary lymphoid structure in esophageal squamous cell carcinoma: a systematic review and meta-analysis review.2025BMC cancerFree full text
  4. RGS16-driven cancer-associated fibroblasts promote esophageal squamous cell carcinoma progression via the MDK-SDC1 axis-mediated intercellular crosstalk.2025Biology directFree full text
  5. Machine learning-based lactate-related genes signature predicts clinical outcomes and unveils novel therapeutic targets in esophageal squamous cell carcinoma.2025Cancer letters
  6. Gene-specific ctDNA dynamics predict tumour burden and survival outcomes in ESCC: A prospective cohort study.2025Clinical and translational medicineFree full text
  7. M2-like Macrophages-derived CCL17 Promotes Esophageal Squamous Cell Carcinoma Metastasis and Stemness via Activating CCR4-mediated ERK/PD-L1 Pathway.2025Current molecular medicineFree full text
  8. Outcomes of endoscopic submucosal dissection versus esophagectomy for poorly differentiated superficial esophageal squamous cell carcinoma: A 10-year cohort study.2025Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  9. Long-term Outcomes of Endoscopic Radiofrequency Ablation versus Endoscopic Submucosal Dissection for Widespread Superficial Esophageal Squamous Cell Neoplasia.2025Gut and liverFree full text
  10. Risk model based on genes regulating the response of tumor cells to T-cell-mediated killing in esophageal squamous cell carcinoma.2024AgingFree full text
  11. EIF4A3-mediated oncogenic circRNA hsa_circ_0001165 advances esophageal squamous cell carcinoma progression through the miR-381-3p/TNS3 pathway.2024Cell biology and toxicologyFree full text
  12. Genome-wide methylation profiling identified methylated KCNA3 and OTOP2 as promising diagnostic markers for esophageal squamous cell carcinoma.2024Chinese medical journalFree full text
  13. Dysregulated inclusion of BOLA3 exon 3 promoted by HNRNPC accelerates the progression of esophageal squamous cell carcinoma.2024Frontiers of medicine
  14. Risk and pathologic factors of recurrence after endoscopic resection for superficial esophageal squamous cell carcinoma: a systematic review and meta-analysis.2024Gastrointestinal endoscopy
  15. Efficacy and safety of pembrolizumab combined with albumin-bound paclitaxel and nedaplatin for advanced esophageal squamous cell carcinoma.2024Immunotherapy
  16. Concerns about pooled performances of cytology for esophageal squamous cell carcinoma screening.2023Gastrointestinal endoscopy
  17. Management of Esophageal Squamous Cell Carcinoma Invading the Muscularis Mucosa or Shallow Submucosal Layer After Endoscopic Resection.2023The American journal of gastroenterology
  18. Machine learning-based automated sponge cytology for screening of oesophageal squamous cell carcinoma and adenocarcinoma of the oesophagogastric junction: a nationwide, multicohort, prospective study.2023The lancet. Gastroenterology & hepatology
  19. Application of an artificial intelligence system for endoscopic diagnosis of superficial esophageal squamous cell carcinoma.2022World journal of gastroenterologyFree full text
  20. Demarcation of early esophageal squamous cell carcinoma during endoscopic submucosal dissection: A comparison study between Lugol's iodine staining and narrow-band imaging.2021MedicineFree full text
  21. SOX12 contributes to the activation of the JAK2/STAT3 pathway and malignant transformation of esophageal squamous cell carcinoma.2021Oncology reportsFree full text
  22. Feasibility and Accuracy of Artificial Intelligence-Assisted Sponge Cytology for Community-Based Esophageal Squamous Cell Carcinoma Screening in China.2021The American journal of gastroenterology
All its trials on ClinicalTrials.gov, any status10
  1. Diagnostic Accuracy of Endocytoscopy for Superficial Esophageal NeoplasiaEnrolling by invitationNCT06984055Lead sponsorStart 2025-03
  2. Cytosponge in Surveillance After Endoscopic Submucosal Dissection for Esophageal Squamous Cell CarcinomaStatus unknownNCT06429865Lead sponsorN/AStart 2024-05
  3. Multimodal Endoscopic Image Fusion for Assessing Infiltration in Superficial Esophageal Squamous Cell CarcinomaStatus unknownNCT06412419Lead sponsorStart 2024-05
  4. China Early Esophageal Cancer CohortStatus unknownNCT06515964Lead sponsorStart 2022-10
  5. Esophageal cAncer Screening TrialCompletedNCT04609813Lead sponsorStart 2021-01
  6. Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System NeoplasmsStatus unknownNCT03468244Lead sponsorN/AStart 2018-05
  7. Changhai Multimodal Esophageal Cancer CohortStatus unknownNCT06410677Lead (inferred)Start 2018-06
  8. Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell CarcinomaRecruitingNCT04135664Study sitePhase 3Start 2019-09
  9. Robot-assisted Esophagectomy Versus Conventional Thoracoscopic EsophagectomyStatus unknownNCT03094351Study sitePhase 3Start 2017-07
  10. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02611700Study sitePhase 3Start 2015-11
More papers found outside PubMed (not counted)7
  1. ESCC-eCura: A Novel Scoring System to Assess Curability after Endoscopic Submucosal Dissection for Superficial Esophageal Squamous Cell Carcinoma2025SSRN Electronic Journalpreprint
  2. Economic evaluation of sponge cytology test vs. endoscopy for esophageal squamous cell carcinoma screening in high-risk areas: a cost-effectiveness study2025The Lancet Regional Health - Western Pacificarticle
  3. Screening and preliminary clinical validation of salivary exosomal mRNA KPNA2 as a novel diagnostic marker for esophageal squamous cell carcinoma2025The Lancet Regional Health - Western Pacificarticle
  4. 101P Safety and effectiveness of pembrolizumab combined with albumin-bound paclitaxel and nedaplatin as first-line treatment in advanced esophageal squamous cell carcinoma patients2022Immuno-Oncology Technologyarticle
  5. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figsharedataset
  6. A phase II study of neoadjuvant immunotherapy combined with chemotherapy (camrelizumab plus albumin paclitaxel and carboplatin) in resectable thoracic esophageal squamous cell cancer (NICE study): Interim results.2021Journal of Clinical Oncologyconference-abstract
  7. Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma2021Annals of Surgeryarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 19 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
19
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 4420222023: 4420232024: 4420242025: 442025

15 hospitals in Shanghai for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging, AI & early detectionRecurrence & prognosisLocal treatment (ablation, TACE, HAIC)
Departments in papersClinical trials / research unitRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led19
  1. Long-read sequencing reveals HBV integration patterns and oncogenic impact on early-onset hepatocellular carcinoma.2025Genome researchFree full text
  2. CD34+CLDN5+ tumor associated senescent endothelial cells through IGF2-IGF2R signaling increased cholangiocellular phenotype in hepatocellular carcinoma.2025Journal of advanced researchFree full text
  3. SCRN1 confers hepatocellular carcinoma resistance to ferroptosis by stabilizing GPX4 via STK38-mediated phosphorylation.2025Nature cancer
  4. COPB2 promotes hepatocellular carcinoma progression through regulation of YAP1 nuclear translocation.2025Oncology researchFree full text
  5. Engineered cell membrane-coated nanoparticles based cancer therapy: A robust weapon against the lethal and challenging hepatocellular carcinoma.2024Biointerphases
  6. Pumilio RNA binding family member 1 deficiency activates anti-tumor immunity in hepatocellular carcinoma via restraining M2 macrophage polarization.2024Cell cycle (Georgetown, Tex.)Free full text
  7. Bioinformatics and experimental verification to explore the potential mechanism of ginsenoside Rg3 suppresses hepatocellular carcinoma progression.2024International immunopharmacology
  8. Sanshimao formula inhibits the hypoxia-induced pro-angiogenesis of hepatocellular carcinoma cells partly through regulating MKK6/p38 signaling pathway.2024The Journal of pharmacy and pharmacology
  9. Fusing Positive and Negative CT Contrast Nanoagent for the Sensitive Detection of Hepatoma.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  10. Hypoxia-induced circ-CDYL-EEF1A2 transcriptional complex drives lung metastasis of cancer stem cells from hepatocellular carcinoma.2023Cancer letters
  11. Aconite aqueous extract inhibits the growth of hepatocellular carcinoma through CCL2-dependent enhancement of natural killer cell infiltration.2023Journal of integrative medicine
  12. Physical exercise suppresses hepatocellular carcinoma progression by alleviating hypoxia and attenuating cancer stemness through the Akt/GSK-3β/β-catenin pathway.2023Journal of integrative medicine
  13. Endothelial Nogo-B Suppresses Cancer Cell Proliferation via a Paracrine TGF-β/Smad Signaling.2022CellsFree full text
  14. Integrated analysis revealing the role of TET3-mediated MUC13 promoter hypomethylation in hepatocellular carcinogenesis.2022Epigenomics
  15. Doxorubicin-liposome combined with clodronate-liposome inhibits hepatocellular carcinoma through the depletion of macrophages and tumor cells.2022International journal of pharmaceutics
  16. Recent advances and applications of microspheres and nanoparticles in transarterial chemoembolization for hepatocellular carcinoma.2022Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyFree full text
  17. Sec62 promotes pro-angiogenesis of hepatocellular carcinoma cells under hypoxia.2021Cell biochemistry and biophysics
  18. m6A RNA Methylation Regulators Elicit Malignant Progression and Predict Clinical Outcome in Hepatocellular Carcinoma.2021Disease markersFree full text
  19. Preparation of Galactosyl Nanoparticles and Their Targeting Efficiency to Hepatocellular Carcinoma.2021Journal of nanoscience and nanotechnology
All its trials on ClinicalTrials.gov, any status3
  1. Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining EmbolotherapyStatus unknownNCT01236690Lead sponsorPhase 2Start 2010-11
  2. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  3. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)CompletedNCT00617981Study sitePhase 3Start 2008-05

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 31 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
31
2021–2025
Trials led
12
any status, ClinicalTrials.gov
Open trials led
5
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 5520222023: 6620232024: 6620242025: 662025

18 hospitals in Shanghai for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer
    Phase
    N/A
    Started
    2024-04
    Registry
    NCT06346093

    Age 18 years to Not stated (registered criteria)

    Led by Changhai HospitalShanghai

  2. Recruiting
    AI-Assisted Non-Contrast CT for Multi-Cancer Screening
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06632886

    Age 18 years to Not stated (registered criteria)

    Led by Changhai HospitalShanghai

  3. Recruiting
    Effect of Premedication With Pronase on Mucosal Cleanliness During EGD
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06713421

    Age 18 years to 70 years (registered criteria)

    Led by Changhai HospitalShanghai

  4. Not yet recruiting
    Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions
    Phase
    Not given
    Started
    2026-03
    Registry
    NCT07507071

    Age 18 years to 75 years (registered criteria)

    Led by Changhai HospitalShanghai

  5. Not yet recruiting
    Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD
    Phase
    Not given
    Started
    2025-07
    Registry
    NCT07088744

    Age 18 years to 80 years (registered criteria)

    Led by Changhai Hospital; 1 listed hospital as study siteChengdu, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapy & targeted drugsPeritoneal spread & advanced diseaseEarly detection & endoscopy
Departments in papersGastroenterology / hepatologyMedical oncologyRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)
Papers it led31
  1. Targeting autophagy to enhance Nectin-4-MMAE efficacy in gastric cancer.2026Biochimica et biophysica acta. Molecular basis of disease
  2. Participation and Yield of Gastric Cancer Screening Programs: A Systematic Review and Meta-analysis.2026Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  3. The IL-17 axis in gastric carcinogenesis: From inflammation to oncogenic transformation.2026Cytokine & growth factor reviews
  4. N6-methyladenosine RNA modification in stomach carcinoma: Novel insights into mechanisms and implications for diagnosis and treatment.2025Biochimica et biophysica acta. Molecular basis of disease
  5. The heterogeneous roles of neutrophils in gastric cancer: scaffold or target?2025Cellular & molecular biology lettersFree full text
  6. Targeting asparagine potentiates anti-PD-L1 immunotherapy in gastric cancer by enhancing CD8+ T cell anti-tumor response.2025Frontiers in immunologyFree full text
  7. Advanced therapies for stomach cancer.2025Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  8. Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives.2025Molecular medicine (Cambridge, Mass.)Free full text
  9. Preclinical development and a phase 1 trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer.2025Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  10. The necroptosis-related signature and tumor microenvironment immune characteristics associated with clinical prognosis and drug sensitivity analysis in stomach adenocarcinoma.2024AgingFree full text
  11. Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer.2024Cancer immunology, immunotherapy : CIIFree full text
  12. In-hospital outcomes of older patients with gastric cancer and their risk factors: large comprehensive institution-based study.2024European geriatric medicine
  13. High-resolution subtyping of fibroblasts in gastric cancer reveals diversity among fibroblast subsets and an association between the MFAP5-fibroblast subset and immunotherapy.2024Frontiers in immunologyFree full text
  14. Chitosan-modified molybdenum selenide mediated efficient killing of Helicobacter pylori and treatment of gastric cancer.2024International journal of biological macromolecules
  15. Optical enhancement mode 2 improves the detection rate of gastric neoplastic lesion in high-risk populations: A multicenter randomized controlled clinical study.2024United European gastroenterology journalRCTFree full text
  16. Assessing synchronous ovarian metastasis in gastric cancer patients using a clinical-radiomics nomogram based on baseline abdominal contrast-enhanced CT: a two-center study.2023Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  17. 68 Ga-PSMA-11 PET/CT and PET/MRI in Rectal Linitis Plastica Secondary to Prostate Adenocarcinoma.2023Clinical nuclear medicine
  18. Bioinformatics Analysis Reveals the Vital Role of AKR1B1 in Immune Infiltration and Clinical Outcomes of Gastric Cancer.2023DNA and cell biology
  19. Clinical value and influencing factors of establishing stomach cancer organoids by endoscopic biopsy.2023Journal of cancer research and clinical oncologyFree full text
  20. Liquid tumor microenvironment enhances WNT signaling pathway of peritoneal metastasis of gastric cancer.2023Scientific reportsFree full text
  21. The value of lymph nodes ratios in the prognosis of resectable remnant gastric cancer through the retrospective propensity score matching analysis.2023World journal of surgical oncologyFree full text
  22. FDG PET/CT in Prostate Metastasis From Gastric Cancer.2022Clinical nuclear medicine
  23. LncRNA CCAT1 Upregulates ATG5 to Enhance Autophagy and Promote Gastric Cancer Development by Absorbing miR-140-3p.2022Digestive diseases and sciences
  24. Identification of N7-methylguanosine related subtypes and construction of prognostic model in gastric cancer.2022Frontiers in immunologyFree full text
  25. Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer.2022Frontiers in immunologyFree full text
  26. Clinical significance of chromosomal integrity in gastric cancers.2022The International journal of biological markers
  27. Differentiating T1a-T1b from T2 in gastric cancer lesions with three different measurement approaches based on contrast-enhanced T1W imaging at 3.0 T.2021BMC medical imagingFree full text
  28. Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer.2021Cell death & diseaseFree full text
  29. Linked Color Imaging Can Improve Detection Rate of Early Gastric Cancer in a High-Risk Population: A Multi-Center Randomized Controlled Clinical Trial.2021Digestive diseases and sciencesRCT
  30. Helicobacter pylori Infection and Serum Pepsinogen Level With the Risk of Gastric Precancerous Conditions: A Cross-sectional Study of High-risk Gastric Cancer Population in China.2021Journal of clinical gastroenterology
  31. Comprehensive analysis of metastatic gastric cancer tumour cells using single-cell RNA-seq.2021Scientific reportsFree full text
All its trials on ClinicalTrials.gov, any status21
  1. Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal LesionsNot yet recruitingNCT07507071Lead sponsorStart 2026-03
  2. Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESDNot yet recruitingNCT07088744Lead sponsorStart 2025-07
  3. Effect of Premedication With Pronase on Mucosal Cleanliness During EGDRecruitingNCT06713421Lead sponsorN/AStart 2024-12
  4. Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric CancerRecruitingNCT06346093Lead sponsorN/AStart 2024-04
  5. Establishment and Effectiveness Evaluation of a Training System for Confocal Laser EndomicroscopyCompletedNCT06981819Lead sponsorStart 2025-06
  6. Confocal Laser Microendoscopy (CellTouch) for the Diagnosis of Early Gastric Cancer: A Multicenter Clinical StudyStatus unknownNCT06152783Lead sponsorStart 2023-11
  7. Setting the Shortest Examination Time of Gastroscopy to Improve the Detection Rate of Upper Gastrointestinal TumorsCompletedNCT04602299Lead sponsorN/AStart 2020-11
  8. Application of OE in Diagnosis of EGCStatus unknownNCT04720521Lead sponsorN/AStart 2019-05
  9. Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System NeoplasmsStatus unknownNCT03468244Lead sponsorN/AStart 2018-05
  10. Application of Linked Color Imaging(LCI) in Diagnosis of Early Gastric Cancer(EGC)Status unknownNCT03661671Lead sponsorN/AStart 2018-01
  11. Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric DiseasesCompletedNCT02219529Lead sponsorPhase 3Start 2014-08
  12. AI-Assisted Non-Contrast CT for Multi-Cancer ScreeningRecruitingNCT06632886Lead (inferred)N/AStart 2024-10
  13. Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric CancerActive, not recruitingNCT06693128Study sitePhase 2Start 2024-11
  14. Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East AsiaCompletedNCT05606094Study siteStart 2023-03
  15. Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 ExpressionStatus unknownNCT05472857Study sitePhase 1Start 2022-08
  16. Laparoscopic-assisted Distal Gastrectomy and Totally Laparoscopic Distal Gastrectomy for Gastric CancerCompletedNCT05541783Study siteN/AStart 2022-09
  17. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  18. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Study sitePhase 2/Phase 3Start 2019-12
  19. XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)CompletedNCT03399110Study sitePhase 3Start 2018-01
  20. Nasal Endoscopic Screening and Risk Assessment for Early Gastric CancerStatus unknownNCT04989153Study siteStart 2016-03
  21. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 2 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

11 hospitals in Shanghai for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 1 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

60 hospitals in Shanghai for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

21 hospitals in Shanghai for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led no English-language PubMed papers on neuroblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

34 hospitals in Shanghai for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led no English-language PubMed papers on IgG4-related disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Shanghai for IgG4-related disease46 hospitals in China for IgG4-related disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease
    Phase
    Early phase 1
    Started
    2025-12
    Registry
    NCT07298590

    Age 18 years to 70 years (registered criteria)

    Led by Changhai HospitalShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Chinese-language papers (not in the count)2
  1. [Pathological significance of plasma cell infiltration in diagnosing lymph node diseases].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [IgG4 related disease presented as spleen mass:report of a case].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status2
  1. An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related DiseaseNot yet recruitingNCT07298590Lead sponsorEarly phase 1Start 2025-12
  2. Tofatib Treatment for IgG4-related DiseaseStatus unknownNCT05625581Lead sponsorStart 2022-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

8 hospitals in Shanghai for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

34 hospitals in Shanghai for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

15 hospitals in Shanghai for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

26 hospitals in Shanghai for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

17 hospitals in Shanghai for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital diaphragmatic hernia

先天性膈疝

Led no English-language PubMed papers on congenital diaphragmatic hernia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Shanghai for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia

No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Adult congenital diaphragmatic hernia with absent pericardium and liver heterotopia.2020European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led no English-language PubMed papers on Hirschsprung disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Shanghai for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Etiological analysis and surgical method selection of adult megacolon].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led 1 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 1.8%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

7 hospitals in Shanghai for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

9 hospitals in Shanghai for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)2
  1. Juvenile polyposis syndrome might be misdiagnosed as familial adenomatous polyposis: a case report and literature review.2020BMC gastroenterology
  2. Difference in the frequency of pouchitis between ulcerative colitis and familial adenomatous polyposis: is the explanation in peripouch fat?2019Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
All its trials on ClinicalTrials.gov, any status1
  1. Colorectal Adenoma Canceration in FAPNot yet recruitingNCT04531930Lead sponsorStart 2020-10

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

海军军医大学第一附属医院(长海医院)

Changhai Hospital

上海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Changhai Hospital of Shanghai; Shanghai Changhai Hospital; Changhai Hospital of Second Military Medical University; Changhai Hospital of Naval Medical University; Changhai Hospital of Traditional Chinese Medicine; a Changhai Hospital of Traditional Chinese Medicine; Changhai Hospital Affiliated to the Second Military Medical University; Changhai Hospital affiliated to Second Military Medical University

Suggest a correctionDownload the data